Test-retest Evaluation of [18F]F-AraG PET
Study Details
Study Description
Brief Summary
This pilot study aims to evaluate the test-retest variability of [18F]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of [18F]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two [18F]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Checkpoint inhibitor therapy has led to impressive clinical successes, providing objective and durable responses in patients with advanced cancers that previously had very few treatment options. Unfortunately, immunotherapy works only in a relatively small fraction of patients with solid tumors.
The current standard of care anatomic imaging adequately assessed treatment efficacy in the pre-immunotherapy era, when tumor volume burden directly correlated with clinical outcomes. However, anatomic imaging is found to be limited due to the cellular and molecular nature of early responses to immunotherapy. PET imaging is a sensitive technique that uses radiolabeled agents to visualize the distribution of specific molecular targets in the body. Based on its ability to pinpoint molecular activity, PET imaging agents that target key players of the immune response could offer a powerful noninvasive tool for evaluation of complex immunologic processes within the body.
[18F]F-AraG was developed as an agent for imaging activated T cells (Namavari et al., 2011)). [18F]F-AraG is a 18F-labeled analog of 9-b-D-Arabinofuranosylguanine a compound that has shown selective accumulation in T cells (Eriksson, et al., 1994) and whose prodrug, nelarabine, is FDA-approved for treatment of patients with T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma. [18F]F-AraG is independent of the type of immunotherapy regimen being administered adoptive cell therapy, checkpoint inhibitors, cancer vaccines or a combination of immunotherapy and conventional medicines. In vivo, real time imaging of activated T cells in solid tumors before and at a timepoint during and after CkIT therapy can help understand the effects of checkpoint blockade therapy. Repeatability, as an estimate of the magnitude of change that distinguishes normal physiologic and measurement variability from true biologic change, is important to interpreting changes encountered on PET scans in the response-to-treatment setting.
This study will establish test-retest variability of [18F]F-AraG uptake in tumors (primary and metastatic sites) and lymphoid tissue in NSCLC patients prior to start of therapy. The results lead to a better understanding of the parameters affecting signal quantitation.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Advanced non small cell lung cancer (NSCLC) patients Patients will undergo two [18F]F AraG PET/CT scans within 7 days of each other prior to receiving treatment |
Drug: [18F]F-ARAG PET
Two imaging sessions
|
Outcome Measures
Primary Outcome Measures
- [18F]F-AraG Test - Re Test [7 days]
• Quantitative assessment of tracer uptake by Standardized Uptake Value (SUV) based measurements within volumes of interest on two consecutive [18F]F AraG PET scans
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients (>18 years old) with a histologically confirmed NSCLC and a candidate to receive immunotherapy as monotherapy or as combination therapy for advanced/metastatic disease.
-
Measurable disease.
-
ECOG performance status of 0, 1 or 2.
Exclusion Criteria:
-
Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives.
-
Pregnant women or nursing mothers.
-
Patients with severe claustrophobia.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Iowa Hospitals and Clinics | Iowa City | Iowa | United States | 52246 |
Sponsors and Collaborators
- CellSight Technologies, Inc.
- University of Iowa Hospitals & Clinics
Investigators
- Principal Investigator: Muhammad Furqan, M.D., Holden Comprehensive Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CST-FARAG-IO-UIOW-201-TRT